C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment)
CPT:
86141
Synonyms
- Cardiac C-Reactive Protein (CRP)
- High-sensitivity CRP
Special Instructions
State patient's sex on the test request form.
Expected Turnaround Time
Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
For more information, please view the literature below.
Specimen Requirements
Specimen
Serum or plasma
Volume
1 mL
Minimum Volume
0.5 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube, gel-barrier tube, lavender-top (EDTA) tube, or green-top (heparin) tube
Collection
Separate serum or plasma from cells within one hour of collection.
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 7 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Gross lipemia
Test Details
Use
Measurement of CRP by high sensitivity CRP assays may add to the predictive value of other markers used to assess the risk of cardiovascular and peripheral vascular disease.2-8
Limitations
Increases in CRP values are nonspecific. CRP is an indicator for a wide range of disease processes and should not be interpreted without a complete clinical history. Recent medical events resulting in tissue injury, infections, or inflammation, which may cause elevated CRP levels, should also be considered when interpreting results. Serial analysis of CRP should not be used to monitor the effects of treatment.
Methodology
Immunochemiluminometric assay (ICMA)
Reference Interval
Average hs-CRP level:1
• Low risk: <1.00 mg/L
• Average risk: 1.00−3.00 mg/L
• High risk: >3.00 mg/L
Footnotes
1. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499-511. 12551878
2. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998; 97(5):425-428. 9490235
3. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336(14):973-979. 9077376
4. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998; 98(8):731-733. 9727541
5. Ridker PM, Glynn RJ, Hennekens CH. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998; 97(20):2007-2011. 9610529
6. Ridker PM, Rifai N, Peffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998; 98(9):839-844. 9738637
7. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997; 17(6):1121-1127. 9194763
8. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference interval and epidemiological applications. Clin Chem. 1997; 43(1):52-58. 8990222
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 120766 | C-Reactive Protein, Cardiac | 30522-7 | 120768 | C-Reactive Protein, Cardiac | mg/L | 30522-7 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf